Legacy Good Samaritan Hospital Surgeons Find BSGI Effective in Determining Extent of Breast Cancer in Patients With Known Diagnosis
Posted on: Monday, 9 June 2008, 09:01 CDT
NEWPORT NEWS, Va., June 9 /PRNewswire/ -- A group of surgeons from Legacy Good Samaritan Hospital (Portland, Oregon) have found Breast-Specific Gamma Imaging (BSGI) has a significant value in the pre-operative assessment for the extent of breast cancer in patients with known diagnosis. The findings were presented at The Society of Black Academic Surgeons Annual meeting held in Cleveland, Ohio.
BSGI is a molecular breast imaging technique used for the early detection of breast cancer and in the differentiation of malignant and benign tumors. It relies on advanced gamma imaging technology and mammographic positioning to optimize results. For this study BSGI was conducted with a commercially available high-resolution gamma camera, the Dilon 6800.
The study evaluated 138 patients with a cancer diagnosis. In this group, additional disease was found in a total of 11 percent of patients. Six percent were in the same breast and 5 percent were in the opposite breast. This finding is very similar to that of an MRI study conducted by Bilimoria from Northwestern University; however, BSGI provided a significantly lower false positive rate of 7 percent compared to 78 percent with the MRI study.
Member of the Legacy Good Samaritan Hospital group of surgeons, Dr. M. Zhou, concluded that BSGI parallels MRI in sensitivity in the preoperative setting, demonstrates better specificity than MRI, and is less expensive than MRI.
About Dilon Technologies
Dilon Technologies Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; Northwestern Memorial Hospital, Chicago; and The Rose, Houston. For more information on Dilon Technologies please visit http://www.dilon.com/.
M. Zhou MD, N. Johnson MD, S. Gruner MD, G.W. Ecklund MD, P. Meunier MD, S. Bryn RN, G. Green MD. Clinical Utility of Breast Specific Gamma Imaging For Evaluating Disease Extent in the Newly Diagnosed Breast Cancer Patient. SBAS 18th Annual Scientific Session, Cleveland, OH, April 18, 2008.
Dilon Technologies Inc.
CONTACT: Nancy F. Morter of Dilon Technologies Inc., cell,+1-757-589-3914, or office, +1-757-269-4910, ext. 302, nfmorter@dilon.com
Web site: http://www.dilon.com/
Source: PRNewswire
Related Articles
- Prototype Breast Cancer Imaging System Could Improve Patient Care
- Standard Register Aligns With SureScripts-RxHub to Provide Clinical Solutions for Better Managing Patient Medications
- Ocean Tomo to Auction Display, Imaging Processing and Printing Technology Patents on 26 June in Amsterdam
- Goodall Hospital Connects Community Physicians Electronically to Successfully Obtain Patient Medication History for Medication Reconciliation Using RcopiaAC By DrFirst
- Breast Cancer Imaging Study Indicates Breast-Specific Gamma Imaging (BSGI) Is a Strong Adjunct Imaging Modality to Mammography and Ultrasound
- Imaging Diagnostic Systems CTLM Technology Presented at Congress of World Society for Breast Health
- House Clinic Now Offers Less Invasive Treatment for Acoustic Neuromas; Gamma Knife(R) Technology at Good Samaritan Hospital Provides Patients Alternative to Surgery
- Guardian Technologies Initiates Clinical Evaluation of 3i(TM) Technology for Medical Applications; Dr. H.K. (Bernie) Huang to Conduct Multi-Phase, Focused Clinical Studies of Breast, Lung, and Brain Imaging
- Nationwide Survey Finds Only 30 Percent of Patients Undergoing Infertility Treatment Are Able to Administer Their Medications With One Injection Per Day
- Biophan Scientists Publish Landmark Study Validating Technology to Enhance Safety and Compatibility of Implanted Medical Devices With Magnetic Resonance Imaging (MRI)
 |
 |
User Comments (0)
RSS Feeds